PMC:7417114 / 87875-90339 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T421","span":{"begin":126,"end":133},"obj":"Body_part"},{"id":"T422","span":{"begin":779,"end":787},"obj":"Body_part"},{"id":"T423","span":{"begin":799,"end":807},"obj":"Body_part"},{"id":"T424","span":{"begin":1642,"end":1644},"obj":"Body_part"},{"id":"T425","span":{"begin":1988,"end":1996},"obj":"Body_part"},{"id":"T426","span":{"begin":2001,"end":2009},"obj":"Body_part"},{"id":"T427","span":{"begin":2262,"end":2265},"obj":"Body_part"}],"attributes":[{"id":"A421","pred":"fma_id","subj":"T421","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A422","pred":"fma_id","subj":"T422","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A423","pred":"fma_id","subj":"T423","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A424","pred":"fma_id","subj":"T424","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A425","pred":"fma_id","subj":"T425","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A426","pred":"fma_id","subj":"T426","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A427","pred":"fma_id","subj":"T427","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"Conclusion\nThere are many factors to consider when repurposing approved drugs for a new indication, and identification of key protein targets that are potently inhibited offers an attractive option for a new therapeutic application. The urgency of need and constraints of time, however, which come with developing effective therapeutic approaches during a pandemic crisis can make it challenging to conduct well-controlled studies with data that definitively attribute efficacy to a drug. Numerous agents, which show promise based on preclinical studies and anecdotal data, are presently under clinical investigation as single agents or in combination with other therapies. Several kinase inhibitors are under clinical investigation for COVID-19 that target key virus-associated proteins as well as proteins that play a role in development of symptoms associated with COVID-19, including pneumonia, fibrosis and inflammation. For optimal drug repurposing, the pharmacokinetics of agents need to be taken into consideration. For instance, drugs that require long-term dosing to achieve optimal drug concentrations and anti-inflammatory effects, may not easily treat the symptoms of COVID-19 due to the immediacy of treatment requirement for afflicted patients. Similarly, adverse effects associated with some kinase inhibitors also need to be considered and may present a challenge for treatment of some COVID-19 patients. However, short-term dosing may minimize these risks.\nRoads less traveled might also be considered over time as an alternative to the current therapies being tested in COVID-19 clinical trials, such as the combination of IL-6 blocking agents (tocilizumab sarilumab) or antiviral therapies (ribavirin, ritonavir-lopinavir, remdesivir, niclosamide), with kinase inhibitors (imatinib, osimertinib, gilteritinib, abemaciclib, afatinib, sunitinib, sorafenib, erlotinib), or the direct combination of kinase inhibitors with each other that target relevant virus-associated proteins and proteins associated with pulmonary health (sunitinib and erlotinib, or afatinib and nintedanib). As historically drug combinations and cocktails have offered substantial clinical benefit in the context of other life-threatening diseases, such as AIDS caused by HIV, there is reason to believe the same approach with drugs shown to safely combine and that have provided some benefit on their own, warrants testing in the context of the current SARS-CoV-2 pandemic."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T768","span":{"begin":737,"end":745},"obj":"Disease"},{"id":"T769","span":{"begin":868,"end":876},"obj":"Disease"},{"id":"T770","span":{"begin":888,"end":897},"obj":"Disease"},{"id":"T771","span":{"begin":912,"end":924},"obj":"Disease"},{"id":"T772","span":{"begin":1181,"end":1189},"obj":"Disease"},{"id":"T773","span":{"begin":1403,"end":1411},"obj":"Disease"},{"id":"T774","span":{"begin":1589,"end":1597},"obj":"Disease"},{"id":"T775","span":{"begin":2247,"end":2251},"obj":"Disease"},{"id":"T776","span":{"begin":2444,"end":2452},"obj":"Disease"}],"attributes":[{"id":"A768","pred":"mondo_id","subj":"T768","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A769","pred":"mondo_id","subj":"T769","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A770","pred":"mondo_id","subj":"T770","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A771","pred":"mondo_id","subj":"T771","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A772","pred":"mondo_id","subj":"T772","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A773","pred":"mondo_id","subj":"T773","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A774","pred":"mondo_id","subj":"T774","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A775","pred":"mondo_id","subj":"T775","obj":"http://purl.obolibrary.org/obo/MONDO_0012268"},{"id":"A776","pred":"mondo_id","subj":"T776","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Conclusion\nThere are many factors to consider when repurposing approved drugs for a new indication, and identification of key protein targets that are potently inhibited offers an attractive option for a new therapeutic application. The urgency of need and constraints of time, however, which come with developing effective therapeutic approaches during a pandemic crisis can make it challenging to conduct well-controlled studies with data that definitively attribute efficacy to a drug. Numerous agents, which show promise based on preclinical studies and anecdotal data, are presently under clinical investigation as single agents or in combination with other therapies. Several kinase inhibitors are under clinical investigation for COVID-19 that target key virus-associated proteins as well as proteins that play a role in development of symptoms associated with COVID-19, including pneumonia, fibrosis and inflammation. For optimal drug repurposing, the pharmacokinetics of agents need to be taken into consideration. For instance, drugs that require long-term dosing to achieve optimal drug concentrations and anti-inflammatory effects, may not easily treat the symptoms of COVID-19 due to the immediacy of treatment requirement for afflicted patients. Similarly, adverse effects associated with some kinase inhibitors also need to be considered and may present a challenge for treatment of some COVID-19 patients. However, short-term dosing may minimize these risks.\nRoads less traveled might also be considered over time as an alternative to the current therapies being tested in COVID-19 clinical trials, such as the combination of IL-6 blocking agents (tocilizumab sarilumab) or antiviral therapies (ribavirin, ritonavir-lopinavir, remdesivir, niclosamide), with kinase inhibitors (imatinib, osimertinib, gilteritinib, abemaciclib, afatinib, sunitinib, sorafenib, erlotinib), or the direct combination of kinase inhibitors with each other that target relevant virus-associated proteins and proteins associated with pulmonary health (sunitinib and erlotinib, or afatinib and nintedanib). As historically drug combinations and cocktails have offered substantial clinical benefit in the context of other life-threatening diseases, such as AIDS caused by HIV, there is reason to believe the same approach with drugs shown to safely combine and that have provided some benefit on their own, warrants testing in the context of the current SARS-CoV-2 pandemic."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T975","span":{"begin":82,"end":83},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T976","span":{"begin":202,"end":203},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T977","span":{"begin":354,"end":355},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T978","span":{"begin":481,"end":482},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T979","span":{"begin":762,"end":767},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T980","span":{"begin":818,"end":819},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T981","span":{"begin":1369,"end":1370},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T982","span":{"begin":1579,"end":1585},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T983","span":{"begin":1971,"end":1976},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T984","span":{"begin":2406,"end":2413},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Conclusion\nThere are many factors to consider when repurposing approved drugs for a new indication, and identification of key protein targets that are potently inhibited offers an attractive option for a new therapeutic application. The urgency of need and constraints of time, however, which come with developing effective therapeutic approaches during a pandemic crisis can make it challenging to conduct well-controlled studies with data that definitively attribute efficacy to a drug. Numerous agents, which show promise based on preclinical studies and anecdotal data, are presently under clinical investigation as single agents or in combination with other therapies. Several kinase inhibitors are under clinical investigation for COVID-19 that target key virus-associated proteins as well as proteins that play a role in development of symptoms associated with COVID-19, including pneumonia, fibrosis and inflammation. For optimal drug repurposing, the pharmacokinetics of agents need to be taken into consideration. For instance, drugs that require long-term dosing to achieve optimal drug concentrations and anti-inflammatory effects, may not easily treat the symptoms of COVID-19 due to the immediacy of treatment requirement for afflicted patients. Similarly, adverse effects associated with some kinase inhibitors also need to be considered and may present a challenge for treatment of some COVID-19 patients. However, short-term dosing may minimize these risks.\nRoads less traveled might also be considered over time as an alternative to the current therapies being tested in COVID-19 clinical trials, such as the combination of IL-6 blocking agents (tocilizumab sarilumab) or antiviral therapies (ribavirin, ritonavir-lopinavir, remdesivir, niclosamide), with kinase inhibitors (imatinib, osimertinib, gilteritinib, abemaciclib, afatinib, sunitinib, sorafenib, erlotinib), or the direct combination of kinase inhibitors with each other that target relevant virus-associated proteins and proteins associated with pulmonary health (sunitinib and erlotinib, or afatinib and nintedanib). As historically drug combinations and cocktails have offered substantial clinical benefit in the context of other life-threatening diseases, such as AIDS caused by HIV, there is reason to believe the same approach with drugs shown to safely combine and that have provided some benefit on their own, warrants testing in the context of the current SARS-CoV-2 pandemic."}

LitCovid-PD-CHEBI

LitCovid-PubTator

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T251","span":{"begin":888,"end":897},"obj":"Phenotype"}],"attributes":[{"id":"A251","pred":"hp_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Conclusion\nThere are many factors to consider when repurposing approved drugs for a new indication, and identification of key protein targets that are potently inhibited offers an attractive option for a new therapeutic application. The urgency of need and constraints of time, however, which come with developing effective therapeutic approaches during a pandemic crisis can make it challenging to conduct well-controlled studies with data that definitively attribute efficacy to a drug. Numerous agents, which show promise based on preclinical studies and anecdotal data, are presently under clinical investigation as single agents or in combination with other therapies. Several kinase inhibitors are under clinical investigation for COVID-19 that target key virus-associated proteins as well as proteins that play a role in development of symptoms associated with COVID-19, including pneumonia, fibrosis and inflammation. For optimal drug repurposing, the pharmacokinetics of agents need to be taken into consideration. For instance, drugs that require long-term dosing to achieve optimal drug concentrations and anti-inflammatory effects, may not easily treat the symptoms of COVID-19 due to the immediacy of treatment requirement for afflicted patients. Similarly, adverse effects associated with some kinase inhibitors also need to be considered and may present a challenge for treatment of some COVID-19 patients. However, short-term dosing may minimize these risks.\nRoads less traveled might also be considered over time as an alternative to the current therapies being tested in COVID-19 clinical trials, such as the combination of IL-6 blocking agents (tocilizumab sarilumab) or antiviral therapies (ribavirin, ritonavir-lopinavir, remdesivir, niclosamide), with kinase inhibitors (imatinib, osimertinib, gilteritinib, abemaciclib, afatinib, sunitinib, sorafenib, erlotinib), or the direct combination of kinase inhibitors with each other that target relevant virus-associated proteins and proteins associated with pulmonary health (sunitinib and erlotinib, or afatinib and nintedanib). As historically drug combinations and cocktails have offered substantial clinical benefit in the context of other life-threatening diseases, such as AIDS caused by HIV, there is reason to believe the same approach with drugs shown to safely combine and that have provided some benefit on their own, warrants testing in the context of the current SARS-CoV-2 pandemic."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T254","span":{"begin":126,"end":141},"obj":"http://purl.obolibrary.org/obo/GO_0006605"},{"id":"T255","span":{"begin":682,"end":699},"obj":"http://purl.obolibrary.org/obo/GO_0033673"},{"id":"T256","span":{"begin":912,"end":924},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T257","span":{"begin":1308,"end":1325},"obj":"http://purl.obolibrary.org/obo/GO_0033673"},{"id":"T258","span":{"begin":1774,"end":1791},"obj":"http://purl.obolibrary.org/obo/GO_0033673"},{"id":"T259","span":{"begin":1916,"end":1933},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"text":"Conclusion\nThere are many factors to consider when repurposing approved drugs for a new indication, and identification of key protein targets that are potently inhibited offers an attractive option for a new therapeutic application. The urgency of need and constraints of time, however, which come with developing effective therapeutic approaches during a pandemic crisis can make it challenging to conduct well-controlled studies with data that definitively attribute efficacy to a drug. Numerous agents, which show promise based on preclinical studies and anecdotal data, are presently under clinical investigation as single agents or in combination with other therapies. Several kinase inhibitors are under clinical investigation for COVID-19 that target key virus-associated proteins as well as proteins that play a role in development of symptoms associated with COVID-19, including pneumonia, fibrosis and inflammation. For optimal drug repurposing, the pharmacokinetics of agents need to be taken into consideration. For instance, drugs that require long-term dosing to achieve optimal drug concentrations and anti-inflammatory effects, may not easily treat the symptoms of COVID-19 due to the immediacy of treatment requirement for afflicted patients. Similarly, adverse effects associated with some kinase inhibitors also need to be considered and may present a challenge for treatment of some COVID-19 patients. However, short-term dosing may minimize these risks.\nRoads less traveled might also be considered over time as an alternative to the current therapies being tested in COVID-19 clinical trials, such as the combination of IL-6 blocking agents (tocilizumab sarilumab) or antiviral therapies (ribavirin, ritonavir-lopinavir, remdesivir, niclosamide), with kinase inhibitors (imatinib, osimertinib, gilteritinib, abemaciclib, afatinib, sunitinib, sorafenib, erlotinib), or the direct combination of kinase inhibitors with each other that target relevant virus-associated proteins and proteins associated with pulmonary health (sunitinib and erlotinib, or afatinib and nintedanib). As historically drug combinations and cocktails have offered substantial clinical benefit in the context of other life-threatening diseases, such as AIDS caused by HIV, there is reason to believe the same approach with drugs shown to safely combine and that have provided some benefit on their own, warrants testing in the context of the current SARS-CoV-2 pandemic."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T645","span":{"begin":0,"end":10},"obj":"Sentence"},{"id":"T646","span":{"begin":11,"end":232},"obj":"Sentence"},{"id":"T647","span":{"begin":233,"end":488},"obj":"Sentence"},{"id":"T648","span":{"begin":489,"end":673},"obj":"Sentence"},{"id":"T649","span":{"begin":674,"end":925},"obj":"Sentence"},{"id":"T650","span":{"begin":926,"end":1023},"obj":"Sentence"},{"id":"T651","span":{"begin":1024,"end":1259},"obj":"Sentence"},{"id":"T652","span":{"begin":1260,"end":1421},"obj":"Sentence"},{"id":"T653","span":{"begin":1422,"end":1474},"obj":"Sentence"},{"id":"T654","span":{"begin":1475,"end":2097},"obj":"Sentence"},{"id":"T655","span":{"begin":2098,"end":2464},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Conclusion\nThere are many factors to consider when repurposing approved drugs for a new indication, and identification of key protein targets that are potently inhibited offers an attractive option for a new therapeutic application. The urgency of need and constraints of time, however, which come with developing effective therapeutic approaches during a pandemic crisis can make it challenging to conduct well-controlled studies with data that definitively attribute efficacy to a drug. Numerous agents, which show promise based on preclinical studies and anecdotal data, are presently under clinical investigation as single agents or in combination with other therapies. Several kinase inhibitors are under clinical investigation for COVID-19 that target key virus-associated proteins as well as proteins that play a role in development of symptoms associated with COVID-19, including pneumonia, fibrosis and inflammation. For optimal drug repurposing, the pharmacokinetics of agents need to be taken into consideration. For instance, drugs that require long-term dosing to achieve optimal drug concentrations and anti-inflammatory effects, may not easily treat the symptoms of COVID-19 due to the immediacy of treatment requirement for afflicted patients. Similarly, adverse effects associated with some kinase inhibitors also need to be considered and may present a challenge for treatment of some COVID-19 patients. However, short-term dosing may minimize these risks.\nRoads less traveled might also be considered over time as an alternative to the current therapies being tested in COVID-19 clinical trials, such as the combination of IL-6 blocking agents (tocilizumab sarilumab) or antiviral therapies (ribavirin, ritonavir-lopinavir, remdesivir, niclosamide), with kinase inhibitors (imatinib, osimertinib, gilteritinib, abemaciclib, afatinib, sunitinib, sorafenib, erlotinib), or the direct combination of kinase inhibitors with each other that target relevant virus-associated proteins and proteins associated with pulmonary health (sunitinib and erlotinib, or afatinib and nintedanib). As historically drug combinations and cocktails have offered substantial clinical benefit in the context of other life-threatening diseases, such as AIDS caused by HIV, there is reason to believe the same approach with drugs shown to safely combine and that have provided some benefit on their own, warrants testing in the context of the current SARS-CoV-2 pandemic."}

LitCovid-PMC-OGER-BB

PMC:7417114 / 87875-90339 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7417114 / 87875-90339 JSON TXT